Skip to main
ABT
ABT logo

Abbott Labs (ABT) Stock Forecast & Price Target

Abbott Labs (ABT) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 47%
Buy 41%
Hold 12%
Sell 0%
Strong Sell 0%

Bulls say

Abbott Laboratories is projected to achieve organic sales growth of 6.0-7.0% by 2025, with consensus estimates suggesting an increase to $44.69 billion, reflecting a 6.4% year-over-year growth. The company has demonstrated strong performance across its various segments, with notable growth in its Electrophysiology and Structural Heart portfolios, contributing to double-digit organic growth rates in critical areas such as Diabetes and Rhythm management. Furthermore, Abbott's commitment to dividend increases for over 50 consecutive years, alongside a well-capitalized balance sheet positioned for potential mergers and acquisitions, underscores a robust outlook for the company's financial future.

Bears say

Abbott Laboratories is facing significant challenges due to continued declines in Covid-19 testing revenue, which fell to $69 million in Q3 2025 from $265 million in Q3 2024, prompting the company to adjust its outlook regarding the impact of these sales. Additionally, macroeconomic factors such as inflation and foreign exchange fluctuations, along with increased competition in the continuous glucose monitoring market, are contributing to a negative financial landscape for the company. The overall performance in Q3 2025 revealed a top-line revenue miss, primarily due to weaker-than-expected results in its diagnostics segment and delays in clinical trials, which further hinder Abbott's growth prospects.

Abbott Labs (ABT) has been analyzed by 17 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 41% recommend Buy, 12% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abbott Labs (ABT) Forecast

Analysts have given Abbott Labs (ABT) a Buy based on their latest research and market trends.

According to 17 analysts, Abbott Labs (ABT) has a Buy consensus rating as of Nov 7, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $146.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $146.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abbott Labs (ABT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.